🔥
Mar 8 • 🙋♀️⁉️Ask Ann 🫵🏼🙋🏻♂️
THE FALSE PROMISE OF ANTIDEPRESSANTS
Let me introduce myself. I'm Dr. Peninah Wood Ph.D. I hold Doctorates in Functional medicine, Nutritional medicine, and Holistic medicine. I am a retired nurse, and I am also a Functional Diagnostic Nutritional Practitioner.
Ann has requested that I post my daily classes here. I will post a recent one that was very popular.
If a pill could fix it, it would’ve worked by now.
THE CHEMICAL IMBALANCE STORY:
It wasn’t discovered. It was marketed.
1. WHEN IT HAPPENED (1960s - 2000s)
1960s - 1970s: The hypothesis is born
Researchers noticed that certain drugs affected serotonin and norepinephrine.
They guessed, not proved, that depression might be caused by low levels of these chemicals.
It was a reverse-engineered idea:
There was no biomarker, no test, no confirmed deficiency.
It was a theory, and even the scientists who proposed it said it was unproven and oversimplified.
1980s: Prozac is developed
Eli Lilly needed a simple, memorable story to differentiate Prozac from older antidepressants.
They had:
- a drug that blocked serotonin reuptake
- no clear mechanism for depression
- no biomarker to test
- no way to prove “correction”
But they had a marketing opportunity.
Late 1980s - 1990s: The marketing era begins
Prozac launches in 1987.
This is when the phrase “chemical imbalance” explodes into public consciousness.
Not through scientific papers.
Through advertising.
TV ads, magazine ads, brochures in doctors’ offices, and pharma reps all repeated the same line:
“Depression is caused by a chemical imbalance. Our drug corrects it.”
This was never scientifically validated, but it was:
- simple
- comforting
- non-stigmatizing
- easy to explain
- easy to sell
And it worked.
2000s: The story collapses scientifically
By the early 2000s, multiple large reviews found:
- no evidence of serotonin deficiency
- no consistent neurotransmitter abnormality
- no biomarker for depression
- no test to diagnose a chemical imbalance
Even leaders in psychiatry began publicly stating:
“The chemical imbalance theory was always a metaphor.”
But the public had already internalized it and bought it.
2. HOW IT HAPPENED (the mechanics of the marketing)
A. Direct-to-consumer advertising
The U.S. and New Zealand are the only countries that allow it.
This meant pharma could speak directly to patients, not just doctors.
Ads said:
- “Depression is a chemical imbalance.”
- “Medication corrects it.”
This bypassed scientific nuance and created a cultural belief.
B. Repetition in medical training
Pharma reps provided:
- free lunches (I've eaten a lot of them).
- free materials
- simplified diagrams
- serotonin cartoons
- “educational” pamphlet
- Doctors were taught a clean, linear story.
It was easy to teach.
Easy to remember.
Easy to prescribe.
C. Media amplification
Journalists repeated the metaphor because:
- it was easy to explain
- it reduced stigma
- it made for good headlines
The media didn’t invent it, they amplified it.
D. Patient relief
People liked the story.
It removed shame.
It offered a biological explanation.
It made suffering feel legitimate.
The story spread because it was emotionally satisfying, not scientifically accurate.
3. WHY IT HAPPENED (the incentives)
A. Pharma needed a simple narrative
You can’t sell: “We don’t know how this works, but it might help.”
You can sell: “You have a chemical imbalance. This fixes it.”
A simple story sells better than a complex truth.
B. Psychiatry needed a biological model
In the 1980s, psychiatry was under pressure to be seen as “real medicine.” A biological explanation gave:
- legitimacy
- insurance reimbursement
- diagnostic authority
- alignment with the rest of medicine
The chemical imbalance metaphor helped psychiatry medicalize mood.
C. Insurance companies needed a quick solution
Medication is:
- cheaper than therapy
- faster than lifestyle change
- easier to standardize
- easier to bill
The chemical imbalance story supported a medication-first system.
D. Patients needed hope
People suffering wanted:
- relief
- validation
- a non-moral explanation
- something to hold onto
The metaphor gave them that.
4. THE RESULT: A CULTURAL BELIEF WITHOUT A BIOMARKER
By the 2000s, the public believed:
- depression = low serotonin
- antidepressants = fix serotonin
But the scientific community had already moved on.
Today, even major psychiatric organizations acknowledge:
- depression is not caused by low serotonin
- there is no chemical imbalance test
- the metaphor was oversimplified
But the story persists because:
- it’s familiar
- it’s comforting
- it’s profitable
- it’s easy
And because no one ever came back to correct it.
Why didn't they correct it?
THE MONEY BEHIND ANTIDEPRESSANTS & PSYCHIATRIC CARE
1. Antidepressant Drug Dollars (U.S. + Global Context)
U.S. Antidepressant Market
- Revenue in the U.S. antidepressant market was projected to reach $6.32 billion in 2025.
- Expected to grow slightly to $6.47 billion by 2030.
Global Antidepressant Market
- Valued at $22.13 billion in 2025.
- Expected to grow to $23.56 billion in 2026 and $32.25 billion by 2031.
- SSRIs alone account for 43.12% of the antidepressant market share.
Interpretation: Antidepressants are a multi‑billion‑dollar recurring revenue stream, dominated by SSRIs, with slow but steady growth. The U.S. is the single largest revenue generator globally.
2. Money Spent on Psychiatric & Mental Health Care (U.S.)
A. Total Mental Health Treatment Spending
- In 2019, U.S. adults spent $106.5 billion on treatment for mental disorders.
- 44 million adults (17.3% of the population) had mental‑health‑related expenditures.
B. Mental Health as Part of Total Healthcare Spending
- 90% of the nation’s $4.9 trillion annual healthcare expenditures go toward people with chronic and mental health conditions. (This includes all chronic disease + mental health, not mental health alone.)
C. State-Level Mental Health Spending
- California spends $6.76 billion annually on mental health services.
- New York spends $4.95 billion.
- Many states spend over $1 billion each (PA, NJ, AZ, MI, TX, MD, OH, MN).
Interpretation: Mental health care is a massive public expenditure, with states pouring billions into psychiatric services, crisis care, outpatient programs, and institutional systems.
3. Putting It Together: The Financial Ecosystem
Antidepressants (Drug Sales Only)
- U.S.: $6.3B/year
- Global: $22–32B/year
Mental Health Treatment (All Services)
- U.S. adults: $106.5B/year
- State mental health agencies: $6.7B (CA), $4.95B (NY), and billions across other states.
The Pattern
- Drug revenue is just the tip of the iceberg.
- The psychiatric care economy, therapy, hospitalizations, evaluations, crisis services, outpatient programs, is an order of magnitude larger.
This is why the system defaults to:
- diagnosis = medication = maintenance = long-term care
instead of: physiology = root cause = resolution = independence.
There is far more money in management than in metabolic literacy.
THE HARM ANTIDEPRESSANTS CAN DO TO THE BRAIN
(Physiology‑literate, research‑grounded, non‑medical‑advice)
1. Neuroadaptation: the brain adjusts against the drug
SSRIs don’t “add serotonin.”
They block reuptake, which forces serotonin to linger longer in the synapse.
The brain responds by:
- downregulating serotonin receptors
- reducing receptor sensitivity
- altering feedback loops
- changing transporter density
This is the same principle as:
- caffeine = adenosine receptor upregulation
- opioids = mu‑receptor downregulation
- nicotine = acetylcholine receptor changes
The brain always tries to restore equilibrium.
This is why stopping the drug can feel worse than starting it.
It’s not “your depression returning.”
It’s the brain recalibrating after being pushed in one direction.
2. Emotional blunting: reduced intensity of both positive and negative emotions
Many people report:
- feeling “flat”
- reduced joy
- reduced motivation
- reduced emotional range
- reduced connection
This isn’t psychological weakness, it’s neurochemical dampening.
When serotonin signaling is artificially elevated:
- downstream dopamine circuits can be suppressed
- reward pathways can become less responsive
- emotional salience can decrease
This is why people say: “I don’t feel sad, but I don’t feel alive.”
3. Sexual dysfunction: persistent changes in arousal and sensation
SSRIs are well‑known to affect:
- libido
- arousal
- orgasm
- genital sensation
For some people, these effects persist even after stopping, a phenomenon sometimes called “post‑SSRI sexual dysfunction” in research literature.
This suggests:
- long‑term receptor changes
- altered nitric oxide signaling
- changes in spinal reflex pathways
Again: adaptation, not “correction.”
4. Withdrawal effects: the brain struggling to rebalance
Withdrawal symptoms can include:
- anxiety
- irritability
- insomnia
- dizziness
- sensory disturbances (“brain zaps”)
- mood swings
These are not signs of a “broken brain.” They are signs of a brain recalibrating after neuroadaptation.
Withdrawal often gets mislabeled as:
- relapse
- recurrence
- “proof you need the drug”
This is one of the most damaging parts of the false promise.
5. Potential impacts on neuroplasticity
Some studies suggest that long‑term SSRI use may:
- alter neurogenesis rates
- change dendritic spine density
- shift synaptic plasticity patterns
These changes are not necessarily “damage,” but they are changes, and they are rarely discussed with patients.
The false promise was: “This restores your brain.”
The reality is: “This changes your brain.”
6. Blunted stress response: altered cortisol and emotional processing
SSRIs can affect:
- amygdala reactivity
- fear processing
- stress hormone rhythms
- emotional learning
This can reduce distress in the short term, but it can also reduce emotional adaptability in the long term.
People describe:
- feeling disconnected from themselves
- feeling less resilient
- feeling “muted”
This is not serotonin deficiency. This is altered neural processing.
7. The deepest harm: symptoms get mislabeled as “you,” not as drug effects
This is the part your community needs most.
When someone experiences:
- numbness
- fatigue
- apathy
- sexual dysfunction
- withdrawal
- emotional flattening
They often think:
- “This is my depression.”
- “This is my disorder.”
- “This is who I am.”
But many of these experiences are drug‑induced neuroadaptations, not personal defects.
This is the core harm of the false promise: It convinces people that the drug’s effects are their identity.
You're sad.
You’re exhausted.
You’re overwhelmed.
You’re not feeling like yourself.
You go in for help, and you walk out with a prescription.
Not because anyone decoded your physiology.
Not because anyone checked your nutrients, sleep architecture, thyroid, blood sugar, or stress load.
But because the system has one dominant tool, and one dominant story.
It sounds scientific.
It feels comforting.
But it was never a discovery, it was a marketing narrative.
There is no test for serotonin in the brain.
There is no test for a chemical imbalance.
There is no lab that can diagnose depression through serotonin levels.
The tests that do exist measure serotonin in the body, not the brain, and they’re used for rare medical conditions, not mental health.
THE PART NO ONE TELLS YOU
People didn’t need a serotonin story.
They need someone to check:
- their sleep debt
- their nutrient status
- their thyroid
- their blood sugar
- their inflammation
- their stress physiology
- their environment
- their unmet needs
- their relationships
These are body problems, not character flaws.
And they were never serotonin problems.
There are tests that measure serotonin in the body, but there is no test that can measure serotonin in the brain, and no test that can diagnose depression, anxiety, or any “chemical imbalance.”
Blood, urine, and even spinal‑fluid serotonin tests exist, but none of them reflect brain serotonin levels.
MPORTANT WARNING
Do NOT stop antidepressants abruptly.
Abruptly stopping antidepressants can cause real, intense withdrawal symptoms because the brain adapts to the medication over time.
If someone wants to come off an antidepressant, they should always talk to a qualified clinician and follow a supervised, gradual taper.
This protects the nervous system and reduces the risk of withdrawal effects.
This is not about fear, it’s about physiology.
The brain adjusts to any long‑term neurochemical shift.
Coming off slowly gives it time to rebalance safely.
2
5 comments
THE FALSE PROMISE OF ANTIDEPRESSANTS
powered by
Suggested communities
Powered by